Comparative genomics of Acinetobacter baumannii and therapeutic bacteriophages from a patient undergoing phage therapy

Mei Liu, Adriana Hernandez-Morales, James Clark, Tram Le, Biswajit Biswas, Kimberly A. Bishop-Lilly, Matthew Henry, Javier Quinones, Logan J. Voegtly, Regina Z. Cer, Theron Hamilton, Robert T. Schooley, Scott Salka, Ry Young and Jason J. Gill ()
Additional contact information
Mei Liu: Texas A&M University
Adriana Hernandez-Morales: Texas A&M University
James Clark: Texas A&M University
Tram Le: Texas A&M University
Biswajit Biswas: Naval Medical Research Center
Kimberly A. Bishop-Lilly: Naval Medical Research Center
Matthew Henry: Naval Medical Research Center
Javier Quinones: Naval Medical Research Center
Logan J. Voegtly: Naval Medical Research Center
Regina Z. Cer: Naval Medical Research Center
Theron Hamilton: Naval Air Station
Robert T. Schooley: University of California, San Diego
Scott Salka: AmpliPhi Biosciences (now Armata Pharmaceuticals)
Ry Young: Texas A&M University
Jason J. Gill: Texas A&M University

Nature Communications, 2022, vol. 13, issue 1, 1-14

Abstract: Abstract In 2016, a 68-year-old patient with a disseminated multidrug-resistant Acinetobacter baumannii infection was successfully treated using lytic bacteriophages. Here we report the genomes of the nine phages used for treatment and three strains of A. baumannii isolated prior to and during treatment. The phages used in the initial treatment are related, T4-like myophages. Analysis of 19 A. baumannii isolates collected before and during phage treatment shows that resistance to the T4-like phages appeared two days following the start of treatment. We generate complete genomic sequences for three A. baumannii strains (TP1, TP2 and TP3) collected before and during treatment, supporting a clonal relationship. Furthermore, we use strain TP1 to select for increased resistance to five of the phages in vitro, and identify mutations that are also found in phage-insensitive isolates TP2 and TP3 (which evolved in vivo during phage treatment). These results support that in vitro investigations can produce results that are relevant to the in vivo environment.

Date: 2022
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-022-31455-5 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-022-31455-5

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-022-31455-5

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().